Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | CASP3 | P42574 | 3/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30229529 | 1.00 | MDM4 (0.51) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL27749256 | 1.00 | MDM4 (0.51) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL18795729 | 1.00 | MDM4 (0.51) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL850332 | 1.00 | MDM4 (0.51) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL24899350 | 0.94 | MDM2 (0.47) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL16100914 | 0.89 | MDM4 (0.54) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL16100911 | 0.89 | MDM4 (0.54) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL850472 | 0.89 | CASP3 (0.50) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL31671078 | 0.89 | MDM4 (0.46) | MDM4TP53CASP3MDM2 | |
| SCHEMBL377537 | 0.87 | MDM4 (0.49) | MDM4TP53CASP3MDM2SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373835-A1 | MACROCYLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023004240-A1 | MACROCYLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-26 | — | — | WO | disclosed |